Since acetylcholinesterase inhibitors (donepezil, tacrine, rivastigmine, and galantamine) remain the only available symptomatic treatments for AD, more effort and emphasis are required to balance efficacy with minimizing adverse side effects in the development of novel drugs for treating the cause of AD progression. The gene discussed is ACHE; the disease is Alzheimer disease.